Eric Karas, serving as Chief Commercial Officer for ARS Pharmaceuticals Inc. (NASDAQ:SPRY), executed a sale of company equity on June 12, 2026. The transaction involved the disposal of 25,000 shares of common stock, resulting in a total value of $250,000. The shares were divested at a price point of $10.00 each.
Regulatory filings indicate that this divestment activity coincided with an acquisition event on the identical date. Mr. Karas acquired 25,000 shares of common stock through the exercise of stock options. The acquisition was executed at an exercise price of $1.50 per share, totaling $37,500. The stock options utilized for this transaction were immediately exercisable and carry an expiration date of May 23, 2032.
The sale was executed pursuant to a Rule 10b5-1 trading plan. Mr. Karas adopted this pre-arranged trading plan on December 11, 2025. The use of this plan is designed to facilitate trades in compliance with insider trading regulations.
Following these transactions, Mr. Karas directly holds 12,176 shares of ARS Pharmaceuticals common stock. This current holding includes 1,861 shares acquired under the company’s 2020 Employee Stock Purchase Plan on December 31, 2025. Additionally, the executive holds derivative securities that represent the right to purchase 519,588 shares of common stock.
Market data indicates the stock was trading at $9.75 at the time of reporting. This price point sits slightly below the $10.00 sale price executed by Mr. Karas. Despite this minor variance, shares have posted a 14% return over the past week. According to InvestingPro analysis, SPRY appears undervalued at current levels. InvestingPro offers 10 additional tips and comprehensive analysis through its Pro Research Report, available for SPRY and 1,400+ US equities.
In related corporate developments, ARS Pharmaceuticals Inc. reported its first-quarter 2026 earnings. The financial results presented a mixed outlook. The company posted an earnings per share of -$0.61. This figure fell short of analysts’ expectations of -$0.49, marking a negative surprise of 24.49%. However, revenue performance slightly exceeded projections. Revenue came in at $22.7 million, just above the forecast of $22.67 million.
In another development, Cantor Fitzgerald raised its price target for ARS Pharmaceuticals shares to $30.00 from $12.00. The firm maintained an Overweight rating on the stock. This adjustment follows a webinar and report focused on the company’s clinical program for chronic spontaneous urticaria flares. These recent developments provide investors with key insights into ARS Pharmaceuticals’ financial performance and future potential.
ARS Pharmaceuticals
Follow
Analyze SPRY
Included in our AI-picked strategies
Review strategies
9.75
+0.16
+1.67%
Closed
15:59:59
USD
9.49
-0.27
-2.77%
After Hours
19:51:04
1D
1W
1M
6M
1Y
5Y
Max
Created with Highcharts 11.4.8
14:00
15:00
16:00
17:00
18:00
19:00
9.6
9.8
10
Analyze SPRY
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Should you invest $2,000 in SPRY right now?
ProPicks AI evaluates SPRY alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if SPRY is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?
See More Stocks